Diode laser cyclophotocoagulation: dose-standardized therapy in end-stage glaucoma

Area of Science:

• Ophthalmology
• Glaucoma Research
• Laser Therapy

Background:

• Traditional ciliary body ablation for end-stage glaucoma (cryotherapy, Nd:YAG laser) often causes pain, inflammation, and unpredictable intraocular pressure (IOP) outcomes.
• Diode laser cyclophotocoagulation (cyclodiode laser) emerged as a potentially less invasive alternative.

Purpose of the Study:

• To evaluate the efficacy and safety of diode laser cyclophotocoagulation for uncontrolled intraocular pressure (IOP) in advanced glaucoma.
• To compare outcomes between half and full standardized doses of cyclodiode laser treatment.

Main Methods:

• Thirty patients with advanced glaucoma and uncontrolled IOP were divided into two groups.
• One group received a half dose, the other a full standardized dose of cyclodiode laser treatment.
• Outcomes assessed included IOP control, visual acuity, postoperative inflammation, and phthisis.

Main Results:

• 90% of patients achieved sustained IOP lowering over a mean follow-up of 10.4 months.
• Full treatment group (Group A) showed a 48% IOP reduction; half treatment group (Group B) showed a 36% reduction.
• Significant IOP reduction was observed even in neovascular glaucoma cases; pain control was achieved in 75% of blind eyes with no significant inflammation.

Conclusions:

• Diode laser cyclophotocoagulation is a simple, safe, and frequently successful method for IOP control in end-stage glaucoma.
• Further research is needed to determine optimal dosage parameters for cyclodiode laser treatment.